ModerateCombined oral contraceptives (COC), third generation×Short-to-medium acting systemic glucocorticoid
Updated · Methodology
Mechanism
Estrogens, including those in oral contraceptives, may prolong the half-life of glucocorticoids, so the clinical effect of prednisone may increase (prednisone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US prednisone label, estrogens may slow the hepatic metabolism of certain corticosteroids (prednisone label, US Food and Drug Administration, FDA). The liver converts 80–100% of prednisone into active prednisolone (prednisone SmPC, AEMPS). Combined oral contraceptives with ethinylestradiol may inhibit the metabolism of prednisolone and raise its plasma levels. The documents do not say by how much (desogestrel/ethinylestradiol label, FDA). Glucocorticoids are moderate inducers of CYP3A4 (prednisone label, FDA). Enzyme inducers can speed up the clearance of contraceptive hormones, but the contraceptive SmPC does not list prednisone among its examples of such inducers (desogestrel/ethinylestradiol SmPC, AEMPS).
Symptoms
When the effect of prednisone increases, its usual adverse effects become more likely, especially at high doses and with long treatment. These include sodium retention with oedema, potassium loss that can cause arrhythmia, weight gain, reduced glucose tolerance, high blood pressure, moon face and truncal obesity (prednisone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Mental changes may also occur: euphoria, irritability, mood swings, sleep disturbances, depression and psychosis (prednisone SmPC, AEMPS).
Management
No Spanish or US document for either drug contraindicates this combination or calls for a dose change because of it. The prednisone documents state only that estrogens, including oral contraceptives, may increase the effect of glucocorticoids (prednisone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and prednisone label, US Food and Drug Administration, FDA). Adjust the prednisone dose to symptoms and individual response, then lower it to the lowest possible maintenance dose (prednisone SmPC, AEMPS), that is, the lowest dose that controls the condition (prednisone label, FDA). With high prednisone doses, give potassium supplements, restrict sodium and monitor blood potassium. During long treatment, the patient needs regular medical follow-up, including an eye examination every 3 months (prednisone SmPC, AEMPS). According to the contraceptive SmPC, women taking enzyme-inducing drugs should temporarily add a barrier method. Prednisone is not among its examples of such drugs (desogestrel/ethinylestradiol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Prednisona, Dacortin 2,5 mg (nº registro 47863), sección 4.5 (2026)– AEMPS, CIMA, nº registro 47863 (Dacortin 2,5 mg comprimidos, Laboratorios Ern), revisión 02/2026 (texto revisado 01/2026), secciones 4.2, 4.4, 4.5, 4.8 y 5.2
- AEMPS: Ficha técnica: Prednisona Cinfa 30 mg (nº registro 75676), sección 4.5 (2026)– AEMPS, CIMA, nº registro 75676 (Prednisona Cinfa 30 mg comprimidos EFG), revisión 02/2026 (texto revisado 01/2026), sección 4.5
- AEMPS: Ficha técnica: Desogestrel/etinilestradiol, Microdiol 0,15 mg/0,03 mg (nº registro 56706), sección 4.5 (2022)– AEMPS, CIMA, nº registro 56706 (Microdiol 0,15 mg/0,03 mg comprimidos, Organon Salud), revisión 10/2022, secciones 4.4 y 4.5
- FDA: Prednisone tablets (Mylan) prescribing information (2026)– FDA, DailyMed setid fec09050-5ac2-451b-a2b9-5a21b2def212 (Mylan Pharmaceuticals, Viatris), revisión 09/2026 (versión 10), Precautions: General Precautions y Drug Interactions (Estrogens, Including Oral Contraceptives; Hepatic Enzyme Inducers, Inhibitors and Substrates)
- FDA: ENSKYCE (desogestrel and ethinyl estradiol) prescribing information (2025)– FDA, DailyMed setid 799fa1d8-4e7b-4b5e-844d-d638896a4b02 (Lupin Pharmaceuticals), versión 4, vigente desde 12/2025, Precautions: Drug Interactions (Effects of Combined Hormonal Contraceptives on Other Drugs)